<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification, inheritance, and clinical manifestations of epidermolysis bullosa simplex&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification, inheritance, and clinical manifestations of epidermolysis bullosa simplex<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification, inheritance, and clinical manifestations of epidermolysis bullosa simplex<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Type, inheritance, gene, product</td> <td class="subtitle1">Cutaneous symptoms</td> <td class="subtitle1">Mucosal involvement</td> <td class="subtitle1">Nails and hair symptoms</td> <td class="subtitle1">Extracutaneous manifestations</td> </tr> <tr class="divider_bottom"> <td> <p><strong>Localized EBS</strong><br/> (previously Weber-Cockayne)</p> <p>AD</p> <p><em>KRT5</em>, <em>KRT 14</em></p> <p>Keratin 5, keratin 14</p> </td> <td> <ul> <li>Most common EBS subtype, with majority of mild cases underdiagnosed </li> <li>Clinical onset usually during infancy or early adulthood, with blistering mainly restricted to hands and feet </li> <li>Plantar keratoderma gradually developing (painful, reduced mobility) </li> <li>EB nevi common, with variable pigmentation and irregular borders, triggered by activation of melanocytes due to tissue damage </li> </ul> </td> <td> <ul> <li>Clinically insignificant blisters within oral cavity during early childhood </li> </ul> </td> <td> <ul> <li>Nails may be thick and dystrophic </li> <li>Hair not affected </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Intermediate EBS</strong><br/> (previously EBS generalized intermediate, EBS Köbner)</p> <p>AD</p> <p><em>KRT5</em>, <em>KRT14</em><br/> (monoallelic missense, nonsense, frameshift, or splice-site pathogenic variants)</p> <p>Keratin 5, keratin 14</p> </td> <td> <ul> <li>Generalized blistering, erosions, crusts presenting at birth, enhanced by heat, humidity, and sweating; tendency to diminish in adolescence, when blistering may become localized to hands and feet; blisters heal with hyperpigmentation </li> <li>Plantar keratoderma </li> <li>EB nevi common </li> </ul> </td> <td> <ul> <li>Rarely eye involvement </li> </ul> </td> <td> <ul> <li>Nails may be thick and dystrophic </li> <li>Hair not affected </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Severe EBS</strong><br/> (previously EBS generalized severe, EBS Dowling-Meara)</p> <p>AD</p> <p><em>KRT5</em>, <em>KRT14</em>, <em>PLEC</em></p> <p>Keratin 5, keratin 14, plectin</p> <p>Characteristic clumping of keratin intermediate filaments shown by transmission electron microscopy</p> </td> <td> <ul> <li>Generalized, extensive (also spontaneous) blistering from birth; congenital, ulcerated areas on hands and feet; common, herpetiform (arciform) pattern of blisters; atrophic scarring, milia formation; crusting/necrotic aspect of lesions often associated or preceded by inflammatory plaques </li> <li>Plantar keratoderma (confluent) </li> <li>EB nevi common </li> <li>Clumping of keratin intermediate filaments in transmission electron microscopy </li> </ul> </td> <td> <ul> <li>Involvement of oral mucosa </li> </ul> </td> <td> <ul> <li>Nails prominently involved (thick and dystrophic) </li> <li>Hair not affected </li> </ul> </td> <td> <ul> <li>Life-threatening condition in the first year of life due to infection, malnutrition, and respiratory failure </li> <li>Gastro-esophageal reflux </li> <li>Growth retardation </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, with mottled pigmentation</strong></p> <p>AD</p> <p><em>KRT5</em>, <em>KRT14</em>, <em>EXPH5 </em></p> <p>keratin 5, keratin 14, exophilin 5</p> </td> <td> <ul> <li>Generalized skin blistering of intermediate severity starting at birth, may improve throughout childhood </li> <li>Gradual development of mottled or reticulate pigmentation unrelated to previous sites of blistering in early childhood </li> <li>Focal keratoses of palms and soles over time </li> </ul> </td> <td> </td> <td> <ul> <li>Dystrophic, thickened nails occur over time </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, migratory circinate erythema</strong></p> <p>AD</p> <p><em>KRT5</em></p> <p>Keratin 5 (frameshift with elongated keratin 5 polypeptide)</p> </td> <td> <ul> <li>Multiple vesicles (hands, legs, feet) from birth onwards, with typical, circinate, migratory pattern (with vesicles and crusts at the advancing edge) on erythematous background later on; postinflammatory (mottled) hyperpigmentation </li> </ul> </td> <td> </td> <td> <ul> <li>Nails may be dystrophic </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, intermediate with cardiomyopathy</strong></p> <p>AD</p> <p><em>KLHL24</em><br/> (50% de novo mutations)</p> <p>Kelch-like member 24</p> </td> <td> <ul> <li>Extensive skin defects on extremities at birth, heal with hypo- and hyperpigmentation and skin atrophy (burn scar-like); blistering diminishes in adulthood, but fragility persists with erosions following mechanical trauma </li> <li>Diffuse or focal plantar keratoderma </li> </ul> </td> <td> </td> <td> <ul> <li>Nail thickening and onychogryphosis (markedly curved and deformed nails resembling ram's horns) </li> <li>Diffuse alopecia in some patients </li> </ul> </td> <td> <ul> <li>Dilated cardiomyopathy reported in young adulthood (annual cardiologic screening recommended) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>Recessive EBS, intermediate or severe with keratin 14 or 5 pathogenic variants</strong></p> <p>AR</p> <p><em>KRT14</em><br/> (biallelic nonsense, missense, or frameshift pathogenic variants)</p> <p><em>KRT5</em><br/> (biallelic loss-of-function or missense mutations)</p> <p>Keratin 14, keratin 5</p> </td> <td> <ul> <li>Severe, generalized skin blistering at birth; absence of keratin 5 leads to widespread blisters and erosions and early lethality </li> <li>Postinflammatory hyperpigmentation </li> </ul> </td> <td> </td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, localized or intermediate with BP230 deficiency</strong></p> <p>AR</p> <p><em>DST</em><br/> (biallelic loss-of-function pathogenic variants with absence of BP230)</p> <p>Bullous pemphigoid antigen 230</p> </td> <td> <ul> <li>Skin blistering from birth or childhood, mostly localized to acral extremities </li> <li>Plantar keratoderma </li> </ul> </td> <td> </td> <td> <ul> <li>Nail dystrophy </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, localized or intermediate with exophilin 5 deficiency</strong></p> <p>AR</p> <p><em>EXPH5</em><br/> (biallelic loss-of-function pathogenic variants)</p> <p>Exophilin 5</p> </td> <td> <ul> <li>Generalized skin blistering at birth or in infancy; blistering tendency to diminish with age, ongoing crusting and scabs </li> <li>Mild, mottled pigmentary changes </li> </ul> </td> <td> </td> <td> </td> <td> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, intermediate with <em>PLEC</em> pathogenic variants</strong></p> <p>AD<br/> <em>PLEC</em><br/> Plectin</p> <p>AR<br/> <em>PLEC1a</em><br/> Plectin isoform (expressed in skin but not in muscles)</p> </td> <td> <ul> <li>Skin blistering at birth (mainly acral but may be widespread) </li> <li>Autosomal dominant subtype (formerly type Ogna): mild course; mainly acral erosions; postlesional, violaceous, and hypopigmented macules </li> <li>Autosomal recessive subtype: intermediate severity </li> <li>Plantar keratoderma </li> </ul> </td> <td> </td> <td> <ul> <li>Dystrophic, thickened nails, sometimes onychogryphosis (markedly curved and deformed nails resembling ram's horns) </li> </ul> </td> <td> <ul> <li>No muscular dystrophy </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, intermediate with muscular dystrophy</strong></p> <p>AR</p> <p><em>PLEC</em><br/> (biallelic loss-of-function variants)</p> <p>Plectin</p> <p>Lack of immunoreactivity for plectin, cleavage deep within the basal pole of basal keratinocytes</p> </td> <td> <ul> <li>Generalized skin blistering from birth, intermediate severity with tendency to diminish with age; atrophic scarring, milia formation </li> <li>Focal plantar keratoderma </li> </ul> </td> <td> <ul> <li>Involvement of oral, ocular, and urethral mucosae </li> <li>Granulation tissue and stenosis of upper respiratory tract and hoarseness may occur </li> <li>Pyloric atresia may be associated </li> </ul> </td> <td> <ul> <li>Nail dystrophy and loss </li> </ul> </td> <td> <ul> <li>Dental anomalies </li> <li>Muscular dystrophy starts at a variable age, ranging from infancy to adulthood, usually life limiting </li> <li>Cardiomyopathy may be associated </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p><strong>EBS, severe with pyloric atresia</strong></p> <p>AR</p> <p><em>PLEC</em><br/> (biallelic loss-of-function variants)</p> <p>Plectin</p> </td> <td> <ul> <li>Generalized blistering of variable severity from birth, atrophic scarring </li> <li>Widespread, full-thickness, congenital absence of skin </li> </ul> </td> <td> <ul> <li>Involvement of oral mucosa </li> </ul> </td> <td> </td> <td> <ul> <li>Gestational hydramnios </li> <li>Pyloric atresia </li> <li>Anemia and growth retardation </li> <li>Neonatal lethal course </li> </ul> </td> </tr> <tr> <td> <p><strong>EBS, localized with nephropathy with CD151 deficiency</strong></p> <p>AR</p> <p><em>CD151</em><br/> (biallelic loss-of-function pathogenic variants)</p> <p>CD151 antigen, a tetraspanin expressed in the basement membrane zone interacting and stabilizing alpha-3 beta-1 integrin and alpha-6 beta-4 integrin</p> </td> <td> <ul> <li>Skin blistering at birth, widespread in pretibial area but also scattered on other body parts (particularly those exposed to trauma) </li> <li>Facial freckling, poikiloderma, skin atrophy, acrogeria on sun-exposed backs of hands </li> </ul> </td> <td> <ul> <li>Erosions of oral mucous membranes </li> <li>Nasolacrimal duct stenosis </li> <li>Esophageal webbing and strictures </li> </ul> </td> <td> <ul> <li>Nail dystrophy </li> <li>Early-onset alopecia </li> </ul> </td> <td> <ul> <li>Nephropathy with proteinuria </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">EBS: epidermolysis bullosa simplex; AD: autosomal dominant; EB: epidermolysis bullosa; AR: autosomal recessive.</div><div class="graphic_reference">References:

<ol>
<li>Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020.</li>
<li>Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103.</li>
</ol></div><div id="graphicVersion">Graphic 129148 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
